ES2552219T3 - Proceso para preparar bisulfato de atazanavir y nuevas formas - Google Patents

Proceso para preparar bisulfato de atazanavir y nuevas formas Download PDF

Info

Publication number
ES2552219T3
ES2552219T3 ES05744537.1T ES05744537T ES2552219T3 ES 2552219 T3 ES2552219 T3 ES 2552219T3 ES 05744537 T ES05744537 T ES 05744537T ES 2552219 T3 ES2552219 T3 ES 2552219T3
Authority
ES
Spain
Prior art keywords
time
atazanavir
crystals
atazanavir bisulfate
bisulfate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES05744537.1T
Other languages
English (en)
Inventor
Soojin Kim
Bruce T. Lotz
Mary F. Malley
Jack Z. Gougoutas
Martha Davidovich
Sushil K. Srivastava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Holdings Ireland ULC
Original Assignee
Bristol Myers Squibb Holdings Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35310244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2552219(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Holdings Ireland ULC filed Critical Bristol Myers Squibb Holdings Ireland ULC
Application granted granted Critical
Publication of ES2552219T3 publication Critical patent/ES2552219T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/127—Preparation from compounds containing pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)

Abstract

Un proceso para preparar bisulfato de atazanavir en la forma de cristales de Forma A, que comprende hacer reaccionar una solución de base libre de atazanavir en un disolvente orgánico, que es acetona o una mezcla de acetona y N-metilpirrolidona, con una primera porción de ácido sulfúrico concentrado en una cantidad para reaccionar con menos de aproximadamente el 15 % en peso de la base libre de atazanavir, agregar semillas de los cristales de Forma A de bisulfato de atazanavir a la mezcla de reacción, como cristales de forma de bisulfato de atazanavir, agregar ácido sulfúrico concentrado adicional en etapas múltiples a una velocidad incrementada de acuerdo con la siguiente ecuación**Fórmula** donde Vtiempo >= Volumen de ácido sulfúrico agregado durante el período de tiempo transcurrido Vtotal >= Volumen total de ácido que representa el 90 % de carga tiempo >= Tiempo transcurrido en la cristalización tiempototal >= Tiempo de cristalización total o tiempo total para cargado de ácido para efectuar la formación de cristales de bisulfato de atazanavir, y secar el bisulfato de atazanavir para formar los cristales de Forma A.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
Se adicionó el ácido sulfúrico restante (17,8 g) durante casi 5 h en cinco etapas de acuerdo con el siguiente protocolo, definido por una ecuación cúbica, mientras se mantiene la temperatura a 40-50 ºC.
La velocidad de cada etapa de adición se determinó de acuerdo con la ecuación cúbica descrita antes y se muestra en la tabla posterior.
TABLA 1
Etapa
ml/kg/h ml(H2SO4)/h g(H2SO4)/h Duración (min)
1
4,62 0,579 1,065 60
2
6,93 0,868 1,597 60
3
16,55 2,073 3,814 60
4
30,26 3,790 6,974 60
5
48,47 6,071 11,171 23
Después de que la adición de H2SO4 se completó, la mezcla se enfrió a 20-25 ºC por al menos 1 h con agitación. La
10 mezcla se agitó a 20-25 ºC por al menos 1h. La sal de bisulfato se filtró y el licor madre se recirculó cuando se necesitó para efectuar la transferencia completa. La torta de filtro se lavó con acetona (5-10 ml/g de base libre; 1200 ml de acetona). La sal de bisulfato se secó en NMT 55 ºC bajo vacío hasta el LOD <1 % para producir un material cristalino.
15 El producto cristalino se analizó por configuraciones de DRXP, CED y AGT y espectro de RMNES y se encontró que son cristales de Forma A (no solvatados) del bisulfato del título (véase Figuras 1 a 5).
TABLA 2
Tabla de Datos Cristalográficos Forma A
T ºC
a(Å) b(Å) c(Å) αº βº γº V(Å3) Z' sg dcalc R
+22
9,861(5) 29,245(6) 8,327(2) 93,56(2) 114,77(3) 80,49(3) 2150(2) 2 P1 1,240 0,06
T = temp ( ºC) para los datos cristalográficos. Z' = número de moléculas de fármaco por unidad asimétrica
20 TABLA 3
Tabla de Parámetros Fraccionales y Sus Desviaciones Estándar Estimadas para la Forma A
Átomo
x y z B(A2)
S1
0,3230(4) 0,5467(1) 0,5608(5) 8,0(1)
O100
0,431(1) 0,5060(3) 0,649(1) 11,1(3)
O102
0,335(1) 0,5498(4) 0,383(1) 12,0(4)
O103
0,360(1) 0,5877(4) 0,655(2) 12,0(4)
O104
0,176(1) 0,5384(4) 0,528(1) 11,8(4)
S51
0,6177(4) 0,4505(1) 0,4003(5) 7,2(1)
O150
0,596(1) 0,4430(4) 0,564(1) 12,5(4)
O152
0,518(1) 0,4921(4) 0,317(1) 13,8(4)
O153
0,588(1) 0,4121(3) 0,289(2) 12,2(4)
O154
0,768(1) 0,4587(4) 0,454(1) 12,1(4)
O4
0,6985(7) 0,1753(3) 0,6456(9) 5,7(2)
O7
0,1687(8) 0,1941(3) 0,3411(9) 6,5(2)
O11
-0,0352(7) 0,2482(3) 0,0308(8) 5,7(2)
O14
0,2280(7) 0,1769(3) -0,233(1) 6,1(2)
O15
0,0399(8) 0,1335(3) -0,330(1) 6,4(2)
O17
0,6169(7) 0,2821(3) 0,963(1) 7,1(2)
O18
0,3750(7) 0,2905(3) 0,9136(9) 6,2(2)
N2
0,5015(9) 0,2182(3) 0,902(1) 4,5(2)
N5
0,4642(8) 0,1647(3) 0,6001(9) 4,2(2)
N9
0,2317(9) 0,2788(3) 0,256(1) 5,1(2)
N10
0,1820(9) 0,2760(3) 0,069(1) 4,6(2)
N13
-0,0148(8) 0,2083(3) -0,280(1) 4,6(2)
N39
-0,087(1) 0,5265(3) 0,272(1) 6,1(3)
C1
0,491(1) 0,2627(4) 0,924(1) 5,5(3)
C3
0,6381(9) 0,1908(3) 0,892(1) 4,0(2)
C4
0,600(1) 0,1764(4) 0,702(1) 4,6(3)
C6
0,420(1) 0,1551(4) 0,403(1) 5,1(3)
C7
0,295(1) 0,1936(4) 0,297(1) 5,1(3)
C8
0,357(1) 0,2400(4) 0,346(2) 5,4(3)
C11
0,051(1) 0,2592(4) -0,028(1) 4,9(3)
16
C12
0,024(1) 0,2531(4) -0,223(1) 4,5(3)
C14
0,094(1) 0,1732(4) -0,280(1) 4,7(3)
C16
0,146(2) 0,0943(5) -0,342(2) 10,9(5)
C19
0,616(1) 0,3313(4) 0,996(2) 8,1(4)
C20
0,701(1) 0,1485(4) 1,025(1) 5,8(3)
C21
0,842(1) 0,1219(5) 1,007(2) 7,9(4)
C22
0,583(2) 0,1160(5) 0,997(2) 8,0(4)
C23
0,748(2) 0,1713(5) 1,215(1) 8,2(4)
C24
0,365(1) 0,1079(4) 0,356(2) 6,6(4)
C25
0,484(1) 0,0691(4) 0,470(1) 6,5(3)
C26
0,643(2) 0,0684(5) 0,520(2) 8,4(5)
C27
0,753(2) 0,0293(6) 0,622(2) 11,4(6)
C28
0,709(3) -0,0044(7) 0,691(3) 15,0(9)
C29
0,553(2) -0,0032(5) 0,644(2) 14,2(7)
C30
0,441(2) 0,0343(5) 0,534(2) 10,8(4)
C31
0,291(1) 0,3229(4) 0,311(2) 5,7(3)
C32
0,177(1) 0,3650(4) 0,259(1) 5,4(3)
C33
0,224(1) 0,4064(4) 0,262(2) 6,3(3)
C34
0,122(1) 0,4487(5) 0,233(2) 6,9(4)
C35
-0,031(1) 0,4469(4) 0,189(1) 4,8(3)
C36
-0,081(1) 0,4043(4) 0,180(1) 5,6(3)
C37
0,019(1) 0,3629(4) 0,218(1) 5,4(3)
C38
-0,136(1) 0,4918(4) 0,170(1) 5,3(3)
C40
-0,170(1) 0,5683(4) 0,279(2) 7,8(4)
C41
-0,318(2) 0,5736(5) 0,158(2) 9,1(5)
C42
-0,376(2) 0,5403(5) 0,035(2) 9,0(5)
C43
-0,283(1) 0,4964(5) 0,039(2) 8,1(4)
C44
-0,096(1) 0,2937(4) -0,345(1) 6,2(3)
C45
-0,258(1) 0,2901(5) -0,366(2) 8,5(4)
C46
-0,085(2) 0,2890(6) -0,530(2) 10,8(5)
C47
-0,057(2) 0,3393(5) -0,265(2) 8,9(5)
O54
0,2347(7) 0,8167(3) 0,8392(8) 5,3(2)
O57
0,7713(8) 0,7950(3) 1,0561(9) 5,9(2)
O61
0,9725(7) 0,7436(3) 0,9141(8) 5,3(2)
O64
0,7062(7) 0,8164(3) 0,427(1) 5,9(2)
O65
0,8911(8) 0,8598(2) 0,535(1) 6,1(2)
O67
0,3150(8) 0,7090(3) 1,184(1) 6,4(2)
O68
0,5587(9) 0,6986(3) 1,377(1) 6,6(2)
N52
0,4313(9) 0,7713(3) 1,271(1) 4,9(2)
N55
0,4709(8) 0,8265(3) 1,0332(9) 4,2(2)
N60
0,7555(8) 0,7179(3) 0,728(1) 4,6(2)
N63
0,9491(8) 0,7852(3) 0,601(1) 4,4(2)
N89
1,026(1) 0,4719(3) 0,711(1) 6,0(3)
C51
0,442(1) 0,7247(4) 1,282(1) 5,4(3)
C53
0,296(1) 0,7996(4) 1,141(1) 5,1(3)
C54
0,3347(9) 0,8159(3) 0,989(1) 4,1(3)
C56
0,519(1) 0,8353(4) 0,887(1) 4,7(3)
C57
0,644(1) 0,7959(4) 0,886(1) 4,5(3)
C58
0,587(1) 0,7494(4) 0,854(1) 5,2(3)
C61
0,884(1) 0,7334(4) 0,766(1) 4,2(3)
C62
0,914(1) 0,7392(4) 0,603(1) 4,4(3)
C64
0,839(1) 0,8196(4) 0,513(1) 4,6(3)
C66
0,785(2) 0,8996(5) 0,433(3) 12,1(7)
C69
0,323(1) 0,6588(4) 1,202(2) 8,8(5)
C70
0,237(1) 0,8409(4) 1,232(1) 5,6(3)
C71
0,092(1) 0,8701(5) 1,080(2) 7,6(4)
C72
0,352(1) 0,8744(4) 1,328(2) 7,1(4)
C73
0,187(1) 0,8195(6) 1,362(1) 8,9(4)
C74
0,570(1) 0,8825(4) 0,907(2) 6,4(3)
C75
0,450(1) 0,9206(4) 0,919(1) 6,3(3)
C76
0,296(2) 0,9236(5) 0,813(2) 8,1(4)
C77
0,188(2) 0,9614(6) 0,826(2) 11,2(5)
C78
0,244(2) 0,9942(6) 0,960(2) 15,2(7)
17
imagen15
imagen16
producto fue 47,7 g (0,0594 mol, 74,3 % mol) de Forma E3 de bisulfato de atazanavir (solvato de trietanol) con CLAR HI = 100,0 (véase Figuras 9 y 10).
TABLA 5
Tabla de Datos Cristalográficos Forma E3
T ºC
a(Å) b(Å) c(Å) αº βº γº V(Å3) Z' sg dcalc R
-23
10,749(5) 13,450(4) 9,250(2) 98,33(2) 95,92(3) 102,82(3) 1277(2) 1 P1 1,223 0,06
T = temp ( ºC) para los datos cristalográficos. Z' = número de moléculas de fármaco por unidad asimétrica
TABLA 6
Tabla de Parámetros Fraccionales y Sus Desviaciones Estándar Estimadas para la Forma E3
Átomo
x y z B(A2) Ocupancia si no es igual a 1
S99
0,5568(1) 0,0760(1) 0,5936(1) 3,45(2)
O1
0,4200(5) 0,5541(4) 0,8496(5) 6,9(1)
O2
0,2889(5) 0,6016(4) 1,0066(6) 8,1(1)
O4
0,7004(4) 0,4509(3) 1,0233(4) 4,23(8)
O8
0,2913(4) 0,2932(3) 1,1074(4) 4,23(8)
O12
0,1057(4) 0,1088(3) 0,9299(4) 4,16(8)
O15'
0,329(1) -0,0602(9) 1,064(1) 4,8(3)* 0,3
O15"
0,324(2) -0,156(1) 1,003(2) 3,2(3)* 0,17
O15
0,3312(7) -0,1150(6) 1,0380(8) 4,9(1)* 0,53
O16
0,1810(5) -0,1433(3) 1,1819(4) 5,7(1)
O86
0,391(1) 0,6646(7) 0,6196(9) 11,5(4)
O89
0,3714(7) 0,5646(5) 0,3408(6) 6,5(2)
O90
0,7502(4) 0,2721(3) 0,8957(5) 4,99(9)
O95
0,4984(4) 0,0446(3) 0,7188(4) 4,50(8)
O96
0,6644(4) 0,0315(3) 0,5660(4) 4,83(8)
O97
0,4651(4) 0,0667(3) 0,4636(4) 5,08(9)
O98
0,6112(5) 0,1957(3) 0,6332(5) 5,9(1)
N2
0,4938(5) 0,6229(3) 1,0921(5) 4,8(1)
N5
0,5365(4) 0,4385(3) 1,1609(4) 3,16(8)
N10
0,2952(4) 0,2239(3) 0,8056(4) 3,17(8)
N11
0,2716(4) 0,1163(3) 0,7961(4) 3,08(8)
N14
0,1336(5) -0,0874(4) 0,9743(5) 4,9(1)
N38
-0,2764(4) 0,0574(3) 0,2878(4) 3,24(8)
C1
0,4011(6) 0,5893(4) 0,9712(7) 5,3(1)
C3
0,6225(5) 0,6026(4) 1,0813(5) 3,9(1)
C4
0,6231(5) 0,4896(3) 1,0873(5) 3,19(9)
C6
0,5220(5) 0,3284(3) 1,1691(5) 3,14(9)
C8
0,4026(5) 0,2632(3) 1,0653(5) 3,21(9)
C9
0,4165(5) 0,2747(4) 0,9050(5) 3,6(1)
C12
0,1740(5) 0,0661(4) 0,8596(5) 3,4(1)
C13
0,1592(5) -0,0523(4) 0,8367(5) 3,8(1)
C15
0,2248(6) -0,1124(5) 1,0627(6) 4,6(1)
C17
0,2720(9) -0,1732(6) 1,2842(7) 7,3(2)
C18
0,1818(9) 0,5715(9) 0,894(1) 11,2(3)
C19
0,7292(7) 0,6818(4) 1,1928(7) 5,8(2)
C20
0,725(1) 0,7914(6) 1,169(1) 10,7(3)
C21
0,8613(9) 0,6645(8) 1,165(1) 10,5(3)
C22
0,710(1) 0,6694(7) 1,3507(8) 10,2(3)
C23
0,5158(5) 0,3135(4) 1,3298(5) 3,8(1)
C24
0,6305(6) 0,3765(4) 1,4359(5) 4,0(1)
C25
0,7519(7) 0,3708(6) 1,4192(7) 6,1(2)
C26
0,8581(7) 0,4279(7) 1,5213(9) 7,9(2)
C27
0,8398(8) 0,4935(6) 1,6375(8) 8,6(2)
C28
0,715(1) 0,5002(6) 1,6576(7) 8,0(2)
C29
0,6112(8) 0,4430(5) 1,5589(6) 6,0(2)
C30
0,3043(5) 0,2519(4) 0,6582(5) 3,6(1)
C31
0,1813(5) 0,2051(4) 0,5532(5) 3,4(1)
C32
0,0645(5) 0,2123(4) 0,5934(5) 3,9(1)
C33
-0,0489(5) 0,1725(4) 0,4957(5) 3,8(1)
20
C34
-0,0441(5) 0,1243(4) 0,3503(5) 3,16(9)
C35
0,0756(5) 0,1176(4) 0,3097(5) 3,9(1)
C36
0,1867(5) 0,1568(4) 0,4095(5) 3,9(1)
C37
-0,1615(5) 0,0853(4) 0,2417(4) 3,11(9)
C39
-0,3885(5) 0,0247(4) 0,1969(5) 3,9(1)
C40
-0,3891(5) 0,0200(4) 0,0470(5) 4,2(1)
C41
-0,2737(6) 0,0469(4) -0,0057(5) 4,1(1)
C42
-0,1596(5) 0,0781(4) 0,0890(5) 3,7(1)
C43
0,0488(6) -0,1114(4) 0,7094(6) 4,6(1)
C44
-0,0819(7) -0,0958(6) 0,7378(9) 6,8(2)
C45
0,0496(9) -0,2266(5) 0,6929(9) 7,8(2)
C46
0,0797(8) -0,0738(5) 0,5667(7) 6,2(2)
C84
0,569(1) 0,7880(9) 0,725(1) 6,3(3)
C85
0,448(1) 0,7726(9) 0,673(2) 8,4(4)
C87
0,204(1) 0,449(1) 0,405(2) 10,6(4)
C88
0,240(1) 0,517(1) 0,316(1) 8,6(3)
C91
0,8826(7) 0,2919(5) 0,8896(8) 5,8(2)
C92
0,9613(7) 0,3439(6) 1,035(1) 7,8(2)
H381
-0,275 0,053 0,403 3,2
H891
0,397 0,602 0,446 6,6
H981
0,658 0,219 0,717 6,6
La mayoría de los hidrógenos se ha omitido; solamente los hidrógenos en N9 y el ácido se incluyen.
Los átomos anisotrópicamente refinados se dan en la forma de parámetro de desplazamiento equivalente isotrópico 5 definido como: (4/3)*[a2*B(1,1) + b2*B(2,2) + c2*B(3,3) + ab(cos gamma)*B(1,2)x + ac(cos beta)*B(1,3) + bc(cos alfa)*B(2,3)].
La Forma E3 se caracteriza por el termograma de calorimetría de exploración diferencial que tiene una endoterma normalmente dentro del intervalo de aproximadamente 89,4 ºC a aproximadamente 96,6 como se muestra en la 10 Figura 11.
La Forma E3 también se caracteriza por una curva de análisis gravimétrico térmico que tiene una pérdida de peso desde aproximadamente 14,7 % a aproximadamente 150 ºC como se muestra en la Figura 11.
15 EJEMPLO 4
Se prepararon formulaciones de cápsula de Configuración C de bisulfato de atazanavir que tienen las siguientes composiciones como se describe posteriormente.
Ingrediente
Granulación Basea ( % p/p) Cápsula de 50 mg (mg/Cápsula) Cápsula de 100 mg (mg/Cápsula) Cápsula de 200 mg (mg/Cápsula)
Bisulfato de atazanavir
63,2 56,84b 113,67b 227,34b
Lactosa, Monohidrato, NF
30,4 27,33c 54,69c 109,35c
Crospovidona, NF
6,0 5,39 10,79 21,58
Estearato de Magnesio, NF
0,4 0,36d 0,72d 1,44d
Agua Purificada, USP o Agua para Inyección, USP
c.s.e c.s.e c.s.e c.s.e
Cápsula Tamaño #4
- 1 cada una - -
Cápsula Tamaño #2
- - 1 cada una -
Cápsula Tamaño #0
- - - 1 cada una
Peso de Relleno Total
100,0 89,9 179,9 359,7
a La Granulación Base de bisulfato de atazanavir para cápsulas (55,5 % p/p como la Base Libre) se utilizó para manufacturar las cápsulas de 50 mg, 100 mg y 200 mg. b Esta cantidad se expresa en los términos de bisulfato de atazanavir a 100 % de potencia, y es igual a 55,5 % p/p como la Base Libre. C La cantidad de lactosa, hidratada variará dependiendo de la pureza de bisulfato de atazanavir y la cantidad de estearato de magnesio usada. d La cantidad de estearato de magnesio usada puede variar desde 0,4 % p/p a 0,8 % p/p. e Esto se usa solamente para procesamiento y se remueve por secado.
La granulación base de bisulfato de atazanavir se preparó como sigue, en la cual el material de Configuración C se formó.
21
imagen17

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
    imagen5
ES05744537.1T 2004-05-04 2005-05-03 Proceso para preparar bisulfato de atazanavir y nuevas formas Active ES2552219T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US56804304P 2004-05-04 2004-05-04
US568043P 2004-05-04
US60753304P 2004-09-07 2004-09-07
US607533P 2004-09-07
US11/119,558 US7829720B2 (en) 2004-05-04 2005-05-02 Process for preparing atazanavir bisulfate and novel forms
US119558 2005-05-02
PCT/US2005/015333 WO2005108349A2 (en) 2004-05-04 2005-05-03 Process for preparing atazanavir bisulfate and novel forms

Publications (1)

Publication Number Publication Date
ES2552219T3 true ES2552219T3 (es) 2015-11-26

Family

ID=35310244

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05744537.1T Active ES2552219T3 (es) 2004-05-04 2005-05-03 Proceso para preparar bisulfato de atazanavir y nuevas formas

Country Status (20)

Country Link
US (3) US7829720B2 (es)
EP (3) EP1755596B9 (es)
JP (1) JP5086069B2 (es)
KR (1) KR101153606B1 (es)
AU (2) AU2005240622B2 (es)
BR (1) BRPI0509595B8 (es)
CA (2) CA2777216A1 (es)
CY (1) CY1116919T1 (es)
DK (1) DK1755596T5 (es)
ES (1) ES2552219T3 (es)
HR (1) HRP20150962T2 (es)
HU (1) HUE026242T2 (es)
IL (1) IL178965A (es)
MX (1) MXPA06012612A (es)
NO (1) NO341013B1 (es)
PL (1) PL1755596T3 (es)
PT (1) PT1755596E (es)
RS (1) RS54284B1 (es)
SI (1) SI1755596T1 (es)
WO (1) WO2005108349A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
TWI415635B (zh) * 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
US7642049B2 (en) 2006-06-30 2010-01-05 Bristol-Myers Squibb Company Method for identifying HIV-1 protease inhibitors with reduced metabolic affects through detection of human resistin polymorphisms
JP2010529196A (ja) 2007-06-12 2010-08-26 コンサート ファーマシューティカルズ インコーポレイテッド アザペプチド誘導体
CN101801348A (zh) * 2007-06-22 2010-08-11 百时美施贵宝公司 含有阿扎那韦的压片组合物
MX2009013499A (es) * 2007-06-22 2010-01-18 Bristol Myers Squibb Co Composiciones comprimidas que contienen atazanavir.
PT2170292E (pt) * 2007-06-22 2014-03-06 Bristol Myers Squibb Holdings Ireland Composições de comprimido contendo atazanavir
JP2010530892A (ja) * 2007-06-22 2010-09-16 ブリストル−マイヤーズ スクイブ カンパニー アタザナビルを含む錠剤組成物
WO2010079497A2 (en) * 2009-01-12 2010-07-15 Hetero Research Foundation Novel polymorph of atazanavir sulfate
WO2011027324A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Polymorphic forms of atazanavir sulfate
RS62600B1 (sr) 2009-10-26 2021-12-31 Merck Sharp & Dohme Čvrste farmaceutske kompozicije koje sadrže inhibitor integraze
WO2011127244A2 (en) 2010-04-09 2011-10-13 Bristol-Myers Squibb Company ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT
EA201390464A1 (ru) 2010-09-28 2013-08-30 Рациофарм Гмбх Способ сухой обработки атазанавира
WO2013014633A1 (en) 2011-07-27 2013-01-31 Ranbaxy Laboratories Limited Process for preparation of atazanavir or its bisulfate salt
US8461347B2 (en) 2011-08-05 2013-06-11 Scinopharm Taiwan, Ltd. Process for preparing form A of atazanavir sulfate
EP2888230A4 (en) * 2012-08-24 2017-07-19 Laurus Labs Private Limited Improved process for the preparation of atazanavir bisulfate
WO2014036690A1 (zh) * 2012-09-04 2014-03-13 上海迪赛诺化学制药有限公司 制备阿扎那韦硫酸氢盐a型结晶的方法
CA2900705A1 (en) * 2013-02-12 2014-08-21 Cipla Limited Process for preparing atazanavir sulphate
CN115215792A (zh) * 2022-06-27 2022-10-21 江西富祥药业股份有限公司 一种制备阿扎那韦或其硫酸盐的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US658435A (en) * 1900-03-22 1900-09-25 William T Ginn Coal-digger.
US4026897A (en) 1974-01-31 1977-05-31 Otsuka Pharmaceutical Company 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives
US3980637A (en) 1975-03-17 1976-09-14 Bristol-Myers Company Production of amoxicillin
DE3403329A1 (de) 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
JPS6186211A (ja) 1984-10-04 1986-05-01 日本碍子株式会社 セラミックス複合構造体及びその製造法
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
US5158777A (en) 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
CA2068402C (en) 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
US5428048A (en) 1993-11-08 1995-06-27 American Home Products Corporation Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
TW483763B (en) 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
KR100486051B1 (ko) * 1996-04-22 2005-09-09 노파르티스 아게 항바이러스활성헤테로시클릭아자헥산유도체
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
GB9715896D0 (en) 1997-07-28 1997-10-01 Sca Packaging Ltd Containers
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
JP2002540102A (ja) 1999-03-22 2002-11-26 ブリストル−マイヤーズ スクイブ カンパニー ｃＧＭＰホスホジエステラーゼの縮合ピリドピリダジン阻害剤
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
AU1304601A (en) 1999-11-11 2001-06-06 Kyorin Pharmaceutical Co. Ltd. Solid preparations for oral use
ATE346613T1 (de) 2000-01-21 2006-12-15 Novartis Pharma Gmbh Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
US6254888B1 (en) 2000-01-28 2001-07-03 Boehringer Ingelheim Pharmaceuticals, Inc. Method for coating pharmaceutical dosage forms
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
CZ20011726A3 (cs) 2000-05-26 2002-02-13 Pfizer Products Inc. Způsob reakční krystalizace, který umoľňuje řídit velikost částic
IL145106A0 (en) 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US6670344B2 (en) 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
MXPA03009588A (es) 2001-04-18 2004-12-06 Nostrum Pharmaceuticals Inc Un recubrimiento novedoso para una composicion farmaceutica de liberacion sostenida.
BR0306928A (pt) 2002-01-15 2004-11-09 Ranbaxy Lab Ltd Composições farmacêuticas estáveis compreendendo inibidores de enzimas conversoras de angiotensina (ace)
KR100456833B1 (ko) 2002-08-01 2004-11-10 주식회사 대웅 아목시실린 및 클라불라네이트를 함유하는 유핵정
TW200534879A (en) 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US20050256314A1 (en) 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US7829720B2 (en) 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US20050288343A1 (en) 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
TWI415635B (zh) 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法

Also Published As

Publication number Publication date
HUE026242T2 (en) 2016-06-28
EP1755596B9 (en) 2016-02-10
BRPI0509595A (pt) 2007-10-16
CY1116919T1 (el) 2017-04-05
WO2005108349A3 (en) 2006-11-02
IL178965A0 (en) 2007-03-08
DK1755596T5 (en) 2016-05-23
AU2010201538B2 (en) 2012-09-06
HRP20150962T2 (hr) 2016-04-08
EP1755596A4 (en) 2010-12-29
RS54284B1 (en) 2016-02-29
AU2005240622A1 (en) 2005-11-17
HRP20150962T1 (en) 2015-10-09
EP2669273A1 (en) 2013-12-04
US7829720B2 (en) 2010-11-09
PT1755596E (pt) 2015-11-19
US20090203630A1 (en) 2009-08-13
US20110124689A1 (en) 2011-05-26
IL178965A (en) 2011-05-31
EP1755596B1 (en) 2015-08-12
JP5086069B2 (ja) 2012-11-28
SI1755596T1 (sl) 2015-10-30
CA2565629C (en) 2012-07-31
AU2010201538A1 (en) 2010-05-13
JP2007536245A (ja) 2007-12-13
MXPA06012612A (es) 2006-12-15
US7838678B2 (en) 2010-11-23
WO2005108349A2 (en) 2005-11-17
EP1755596A2 (en) 2007-02-28
BRPI0509595B1 (pt) 2019-05-14
AU2005240622B2 (en) 2010-02-11
CA2777216A1 (en) 2005-11-17
DK1755596T3 (en) 2015-11-16
EP2980074A1 (en) 2016-02-03
KR101153606B1 (ko) 2012-06-11
PL1755596T3 (pl) 2016-04-29
CA2565629A1 (en) 2005-11-17
KR20070006935A (ko) 2007-01-11
US8513428B2 (en) 2013-08-20
NO341013B1 (no) 2017-08-07
US20050256202A1 (en) 2005-11-17
NO20065441L (no) 2006-11-27
BRPI0509595B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
ES2552219T3 (es) Proceso para preparar bisulfato de atazanavir y nuevas formas
AU2020294308B2 (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
TW531531B (en) Bisulfate salt of HIV protease inhibitor and pharmaceutical compositions containing the same
CN103502203B (zh) 制备l-鸟氨酸苯基乙酸盐的方法
RU2385325C2 (ru) Способ получения сульфата атазанавира
JP2007302658A (ja) イマチニブメシレートの多形フォーム及び新規結晶フォーム及び非晶フォーム並びにフォームαの調製方法
SU1480766A3 (ru) Способ получени кристаллического торасемида
JP6554617B2 (ja) １−（５−（２，４−ジフルオロフェニル）−１−（（３−フルオロフェニル）スルホニル）−４−メトキシ−１ｈ−ピロール−３−イル）−ｎ−メチルメタンアミン塩の新規な結晶形
CN105992761A (zh) 具有血小板生成素受体激动作用的光学活性的化合物及其中间体的制备方法
US10898461B2 (en) Salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl) phenoxy]ethyli-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same
CN106795174A (zh) 一种抗病毒活性双氮氧杂环螺二酮哌嗪生物碱衍生物及其制备方法
CN109912525A (zh) 一种lcz696新晶型及其制备方法
WO2011158255A1 (en) Process for preparation of stable imatintb mesylate alpha form
US2834782A (en) Monocalcium monopiperazine salt of ethylenediaminetetracetic acid
US11254666B2 (en) Compound as GLS1 inhibitor
KR20210025000A (ko) 티오펜 유도체의 결정형
WO2017170885A1 (ja) 新規なヒドロキサム酸誘導体の結晶、それらの製造方法および医薬用組成物
JPS6261587B2 (es)
CA1254569A (en) Sulfonic acid salts of 6-amino-1,5-dihydro-4h- imidazo¬4,5-c|pyridin-4-one
US20220087966A1 (en) Mechanosynthesis of a Co-Amorphous Formulation of Creatine with Citric Acid and Humidity-Mediated Transformation into a Co-Crystal
US780619A (en) Morphin compound and process of making same.
JP3259196B2 (ja) ２−ヒドラジノ−４，６−ジメトキシピリミジンの製造法
JP2004091442A (ja) 水溶性クエン酸マグネシウム含水塩およびその製法
JPS5916873A (ja) ５−オキソ−２−ピロリジンプロパン酸および誘導体
CS270272B1 (cs) Způsob výroby ethylesteru kyseliny 3-ethoxy-3-iminopropionové